Chronic Progressive External Ophthalmoplegia Clinical Presentation
- Author: Michael Mercandetti, MD, MBA, FACS; Chief Editor: Hampton Roy, Sr, MD more...
Chronic progressive external ophthalmoplegia (CPEO) tends to begin in young adulthood. Ptosis usually is the first clinical sign, and ophthalmoplegia may not become apparent for months to years. The ptosis is usually bilateral and symmetrical. As the ptosis progresses, the patient may use the frontalis muscle to elevate the eyelids, adopt a chin-up head position, and eventually resort to manual elevation of the eyelids, as ptosis often becomes complete. Cases have been documented of patients who develop ophthalmoplegia but not ptosis. Unilateral or asymmetric ptosis may develop.
Because of the symmetric nature of this disorder, patients often do not complain of diplopia. They may be unaware of their decreased motility until it becomes severe. In many cases, downward gaze is preserved to a greater extent than up-gaze or horizontal movement. The course of CPEO is characterized by constant progression without periods of remission or exacerbation. Patients also may complain of dryness of the eyes due to exposure keratopathy.
In contrast to myasthenia gravis, patients with CPEO usually report little to no variability in their ptosis.
In KSS, children are usually healthy at birth. Boys and girls are affected equally. CPEO and pigmentary retinopathy appear before age 20 years. The retinal pigment undergoes atrophy, usually in a salt-and-pepper pattern without the bony spicule formation typical of retinitis pigmentosa. Ophthalmoplegia generally precedes the development of cardiac conduction disturbances. Sudden death may occur from these disturbances, and patients should have regular cardiac exams, regardless of age. Patients also may have the following: intraventricular septal hypertrophy, mitral valve prolapse, and left ventricular dysfunction.
Weakness of somatic muscles is often noted with progressive facial muscle weakness and neck and shoulder weakness. Extremities tend to be involved to a lesser degree.
Neurologic abnormalities may include the following:
Vestibular dysfunction and/or hearing loss
Endocrine dysfunction is common and may include the following:
A complete ophthalmologic examination should be performed, to include the following:
Dilated retinal examination
Cranial nerve testing
Forced duction testing
In KSS, the salt-and-pepper retinopathy usually occurs initially in the posterior fundus. Pallor of the optic disc, attenuation of retinal vessels, visual field defects, and posterior cataract formation common to retinitis pigmentosa rarely, if ever, occur.
CPEO must be differentiated from myasthenia gravis, Graves disease, and oculopharyngeal dystrophy. The table presented below may also be helpful for categorizing physical findings.
Note the image below.
The mitochondrial myopathies and encephalopathies are a complex group of disorders arising from mtDNA mutations. Little correlation exists between the size and the location of the deletion and the clinical phenotype (ie, CPEO vs KSS). Mutations usually occur sporadically, but they also can be inherited as a point mutation of maternal mitochondrial tRNA or as autosomal dominant and autosomal recessive deletions of mtDNA.
The authors have sequenced the entire mitochondrial DNA (mtDNA) from a 54-year-old man with chronic progressive ophthalmoplegia and hyperCKemia.
Chinnery PF. Mitochondrial Disorders Overview. GeneReviews® [Internet]. Available at http://www.ncbi.nlm.nih.gov/books/NBK1224/. August 14, 2014; Accessed: June 19.2016.
Bresolin N, Bet L, Binda A, et al. Clinical and biochemical correlations in mitochondrial myopathies treated with coenzyme Q10. Neurology. 1988 Jun. 38(6):892-9. [Medline].
Chen T, Pu C, Shi Q, Wang Q, Cong L, Liu J, et al. Chronic progressive external ophthalmoplegia with inflammatory myopathy. Int J Clin Exp Pathol. 2014. 7 (12):8887-92. [Medline].
Ogasahara S, Nishikawa Y, Yorifuji S, et al. Treatment of Kearns-Sayre syndrome with coenzyme Q10. Neurology. 1986 Jan. 36(1):45-53. [Medline].
Carlow TJ, Depper MH, Orrison WW Jr. MR of extraocular muscles in chronic progressive external ophthalmoplegia. AJNR Am J Neuroradiol. 1998 Jan. 19(1):95-9. [Medline].
Ohnuki Y, Takahashi K, Iijima E, Takahashi W, Suzuki S, Ozaki Y, et al. Multiple deletions in mitochondrial DNA in a patient with progressive external ophthalmoplegia, leukoencephalopathy and hypogonadism. Intern Med. 2014. 53 (12):1365-9. [Medline].
Kiyomoto BH, Tengan CH, Moraes CT, et al. Mitochondrial DNA defects in Brazilian patients with chronic progressive external ophthalmoplegia. J Neurol Sci. 1997 Nov 25. 152(2):160-5. [Medline].
Understanding Mitochondrial Disease. United Mitochondrial Disease Foundation. Available at http://www.umdf.org/site/pp.aspx?c=8qKOJ0MvF7LUG&b=7934639. Accessed: 6/19/2016.
Ahn J, Kim NJ, Choung HK, et al. Frontalis sling operation using silicone rod for the correction of ptosis in chronic progressive external ophthalmoplegia. Br J Ophthalmol. Sept 11,2008.
Souilem S, Chebel S, Mancuso M, et al. A novel mitochondrial tRNA(Ile) point mutation associated with chronic progressive external ophthalmoplegia and hyperCKemia. J Neurol Sci. 2011 Jan 15. 300(1-2):187-90. [Medline].
Domenis DR, Granzotti RB, Sobreira CF, Dantas RO. Pharyngeal transit in patients with chronic progressive external ophthalmoplegia. Int J Speech Lang Pathol. 2015 Aug. 17 (4):384-9. [Medline].
De Coo IF, Gussinklo T, Arts PJ, et al. A PCR test for progressive external ophthalmoplegia and Kearns-Sayre syndrome on DNA from blood samples. J Neurol Sci. 1997 Jul. 149(1):37-40. [Medline].
Peterson PL. The treatment of mitochondrial myopathies and encephalomyopathies. Biochim Biophys Acta. 1995 May 24. 1271(1):275-80. [Medline].
Cohen JM, Waiss B. Combination ptosis crutch and moisture chamber for management of progressive external ophthalmoplegia. J Am Optom Assoc. 1997 Oct. 68(10):663-7. [Medline].
Soejima K, Sakurai H, Nozaki M, et al. Surgical treatment of blepharoptosis caused by chronic progressive external ophthalmoplegia. Ann Plast Surg. 2006 Apr. 56(4):439-42. [Medline].
Wallace DK, Sprunger DT, Helveston EM, et al. Surgical management of strabismus associated with chronic progressive external ophthalmoplegia. Ophthalmology. 1997 Apr. 104(4):695-700. [Medline].
Ewart RM, Burrows RF. Pregnancy in chronic progressive external ophthalmoplegia: a case report. Am J Perinatol. 1997 May. 14(5):293-5. [Medline].
Fraunfelder FT, Roy FH, Randall J. Chronic progressive external ophthalmoplegia. Current Ocular Therapy. 5th ed. 2000. 208-210.
Galetta F, Franzoni F, Mancuso M, Orsucci D, Tocchini L, Papi R, et al. Cardiac involvement in chronic progressive external ophthalmoplegia. J Neurol Sci. 2014 Oct 15. 345 (1-2):189-92. [Medline].
Progressive external ophthalmoplegia. NIH U.S. National Library of Medicine. Genetics Home Reference. Available at https://ghr.nlm.nih.gov/condition/progressive-external-ophthalmoplegia. May 2016; Accessed: June 7, 2016.